Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Arimoclomol (Primary)
- Indications Inclusion body myositis
- Focus Therapeutic Use
- 30 Aug 2017 Status changed from not yet recruiting to recruiting.
- 04 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Aug 2017.
- 24 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.